Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.48 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | HCK | P08631 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27975672 | 0.86 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL15283278 | 0.83 | KEAP1 (0.50) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL3716276 | 0.82 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL18985959 | 0.81 | KEAP1 (0.63) | CYP3A4TDP1KEAP1PIK3CDPIK3CA | |
| SCHEMBL29133162 | 0.81 | KEAP1 (0.46) | ALDH1A1TSHRHSD17B10KEAP1PIK3CD | |
| SCHEMBL29598492 | 0.81 | KMO (0.48) | ALDH1A1TSHRHSD17B10KEAP1PIK3CD | |
| SCHEMBL29598549 | 0.81 | SCN4A (0.50) | ALDH1A1KEAP1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16910765 | 0.79 | KDM4E (0.50) | ALDH1A1KEAP1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL20092476 | 0.78 | ALDH1A1 (0.56) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL25589659 | 0.78 | ALDH1A1 (0.56) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| EP-3575299-B1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-07-20 | — | — | EP | disclosed |
| US-11236084-B2 | Substituted azaindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-01 | — | — | US | disclosed |
| EP-3915986-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Voronoi Inc. (KR) | 2021-12-01 | — | — | EP | disclosed |
| EP-3649127-B1 | SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-08 | — | — | EP | disclosed |
| US-20210188840-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | US | disclosed |
| EP-3575299-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | Cancer Research Technology Limited (GB) | 2019-12-04 | — | — | EP | disclosed |
| EP-3575299-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | Cancer Research Technology Limited (GB) | 2019-12-04 | — | — | EP | disclosed |
| US-10399974-B2 | N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| US-10399974-B2 | N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-07-12 | — | — | US | disclosed |
| US-9902721-B2 | N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902721-B2 | N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902721-B2 | N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| EP-3110816-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | Cancer Research Technology Ltd (GB) | 2017-01-04 | — | — | EP | disclosed |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-12-15 | — | — | US | disclosed |
| WO-2015128676-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015128676-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | TTK, TTBK1, TTBK2 | ALDH1A1 3055/4885CYP3A4 1966/4885TSHR 2992/4885 |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | BUB1, BUB1B, CDK1 | ALDH1A1 3310/4885CYP3A4 4494/4885TSHR 2941/4885 |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | BUB1, BUB1B, CDK1 | ALDH1A1 3310/4885CYP3A4 4494/4885TSHR 2941/4885 |
| US-11236084-B2 | Substituted azaindoline derivatives as NIK inhibitors | MAP3K14, NFKBIA, MAP3K15 | ALDH1A1 3603/4885CYP3A4 2938/4885TSHR 4038/4885 |
| US-10399974-B2 | N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | BUB1, BUB1B, CDK1 | ALDH1A1 3310/4885CYP3A4 4494/4885TSHR 2941/4885 |
| US-20210188840-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, MAP3K14 | ALDH1A1 3864/4885CYP3A4 3460/4885TSHR 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.